Filing Flows › 60 Degrees Pharmaceuticals (SXTP) › Q2 2026 › vs Q1 2026
60 Degrees Pharmaceuticals (SXTP) Q2 2026 vs Q1 2026 (quarter over quarter)
60 Degrees Pharmaceuticals's revenue rose $46K (+28%) from $162K in Q1 2026 to $208K in Q2 2026.
60 Degrees Pharmaceuticals, Q2 2026: revenue $208K (+106% year over year), net loss $2.3M, operating cash flow −$2.2M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $208K | $162K | $46K | +28% |
| Other income, net | $6K | $5K | $1K | +15% |
| Net loss | $2.3M | $2.1M | $175K | +8% |
| Costs & expenses | $2.5M | $2.3M | $222K | +10% |
| Operating costs | $2.5M | $2.3M | $222K | +10% |
| Cost of revenue | $151K | $86K | $65K | +76% |
| Research & development | $599K | $281K | $317K | +113% |
| General & admin | $1.7M | $1.9M | −$161K | -8% |
| Operating cash sources | $2.4M | $2.9M | −$531K | -18% |
| Depreciation & amortization | $31K | $26K | $5K | +19% |
| Share-based compensation | $98K | $124K | −$26K | -21% |
| Cash used in operations | $2.2M | $2.7M | −$510K | -19% |
| Net loss absorbed | $2.3M | $2.1M | $175K | +8% |
| Working capital & other | $95K | $801K | −$706K | -88% |
Questions
How much did 60 Degrees Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
60 Degrees Pharmaceuticals's revenue rose $46K (+28%) from $162K in Q1 2026 to $208K in Q2 2026.